Sol-Gel Technologies (SLGL) Assets Average (2017 - 2026)
Sol-Gel Technologies (SLGL) posted quarterly Assets Average of $44.2 million for Q1 2026, up 40.63% year-over-year from $31.5 million in Q1 2025, and up 37.14% quarter-over-quarter from $32.3 million in Q4 2025.
Sol-Gel Technologies (SLGL) Assets Average (2017 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Assets Average for 10 consecutive years, with $44.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 40.63% year-over-year to $44.2 million; the TTM figure through Mar 2026 stood at $44.2 million (up 40.63% YoY), while the FY2025 annual figure was $32.9 million, down 18.94% from the prior year.
- Assets Average rose to $44.2 million in Q1 2026 per SLGL's latest filing, from $32.3 million in the prior quarter.
- Across five years, Assets Average topped out at $62.6 million in Q1 2022 and bottomed at $31.5 million in Q1 2025.
- Historically, Assets Average has averaged $44.9 million across 5 years, with a median of $44.2 million in 2026.
- Annual changes were most pronounced in 2025 — Assets Average dropped 26.16% — and 2026, when it surged 40.63%.
- Sol-Gel Technologies' Assets Average stood at $49.0 million in 2022, then retreated by 2.83% to $47.6 million in 2023, then slipped by 17.16% to $39.4 million in 2024, then fell by 18.16% to $32.3 million in 2025, then jumped by 37.14% to $44.2 million in 2026.
- Business Quant data shows SLGL's Assets Average at $44.2 million in Q1 2026, $32.3 million in Q4 2025, and $36.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Sol-Gel Technologies | 240.26 Mn | 230.12 Mn | - | 44.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 44.23 Mn |
| Dec 31, 2025 | 32.25 Mn |
| Sep 30, 2025 | 36.95 Mn |
| Jun 30, 2025 | 33.19 Mn |
| Mar 31, 2025 | 31.45 Mn |
| Dec 31, 2024 | 39.41 Mn |
| Sep 30, 2024 | 42.49 Mn |
| Jun 30, 2024 | 40.96 Mn |
| Mar 31, 2024 | 42.60 Mn |
| Dec 31, 2023 | 47.57 Mn |
| Sep 30, 2023 | 52.48 Mn |
| Jun 30, 2023 | 52.07 Mn |
| Mar 31, 2023 | 47.84 Mn |
| Dec 31, 2022 | 48.96 Mn |
| Sep 30, 2022 | 53.14 Mn |
| Jun 30, 2022 | 55.52 Mn |
| Mar 31, 2022 | 62.62 Mn |
| Dec 31, 2021 | 61.01 Mn |
| Sep 30, 2021 | 49.62 Mn |
| Jun 30, 2021 | 50.01 Mn |